Member Info for RayPointer

Welcome back crumbs :-)

Hi WTP

https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=C9FE76AF5934EB7BB87F8172D0B6A8E5.wapp2nA?docId=WO2021019094&tab=PCTDESCRIPTION

The patent you highlighted last night relates to Avidimab.
The link above is the description of Avidimab within that patent and it reads very much like a scientific paper.

But the basis of Avidimab is to make small changes with the Fc part of the antibody. This is the down stroke of the Y (antibodies are Y shaped). The idea is to cause an attraction between 2 or more adjacent Fc parts of the antibodies that are trying to bind to a target. This attraction (described by CH as holding hands) makes it more likely that the individual antibodies will bind to the target.
So, instead of antibodies working in isolation to each other they link together and work as a team.

I've always favoured a buyout for Scancell but it must be at the right time.
First of all, we need that elusive pivotal year (PY) to get closer to a buyout possibility. The PY must include getting 1 or more trails going and getting patients enrolled.
Is 2021 the PY? Well yet again we have to wait and see.
But IMO a PY must be followed for 1 or 2 more PYs to get data flowing through and, or course, that must be very good data.

So, lets have 3 PYs Scancell funded by the current bank balance and then a buyout at a record breaking price.
My contribution to the dream discussions :-)

Of course, a deal or 2 along the way will help enormously.

Burble, whatever happens to your current project funding , good luck and I really hope you land on your feet.
IMO, the UK Gov should step in quickly to make up the shortfall of funding. Important scientific projects should not have to rely on funding from charities.

Share prophets - isn't that the idiot a*sehole TW?

Hi WTP

Professor Peter James was the guy Vulpes used to perform much of the scientific due diligence.

https://portal.research.lu.se/portal/en/persons/peter-james(8077bacb-7d2e-4c23-ae03-479036c7d2a1).html

It wouldn't surprise me that CRUK have done nothing with SCIB2 so it is better to have it in house where we know that Avidimab can now we applied and possibly the same delivery method as Covidity.
Gi

Hi Ivy
If you look at the daily candles you will see that both today's and yesterday's were at the open offer price.
Probably more relevant is that they were also at the top of the recent gap up that was much talked about
Looks like a support level to me that traders readily recognise.

Brilliant sidestep :-)

https://www.youtube.com/watch?v=jVK1XU8k2AA

I always considered Covidity a long shot to make it as far as an approved vaccine.

Having said that, we have a platform that we designed to produce cancer vaccines and, as such, Lindy has designed it to produce high avidity T Cells. This appears to be a definite requirement for a vaccine to have any affect on late stage cancers.
With the addition of Avidimab, it looks like it makes the platform even more potent.

The missing piece of the jigsaw is, of course, the delivery mechanism. This needs to maintain the dual presentation aspect of Immunobody to retain the high avidity of the resultant TCells. I'm guessing that this is not an easy thing to develop so this is what is taking the time.

So, there may well be vaccines being developed that target both S and N proteins but do they
a) provide T Cells of the same high avidity that Immunobody provides?
b) provide the flexibility of Immunobody of adding/deleting targets as required?
c) provide lasting immunity via those all important long lasting memory TCells (presumably inheriting the same high avidity)?

Thanks Northern
Yes that's my understanding too.

I think possibly the next RNS will celebrate the first copper concentrate being processed at Sable.
Then the SP will shoot up to 23p :-)

I like Knowlesi. He keeps us all honest :-)

I don't recall the Health Secretary ever mentioning a list of particular postcodes that require extra vigilance and the need for door to door testing. So it sounds as though they are worried about the SA variant.

No need to be sorry 3cb. BBs are there to spread knowledge around and this BB is particularly good at that with a number of very knowledgeable posters (I do not count myself among that group) :-)

Not that I know of. If we do, I suspect it is a very small percentage of the PGM basket. I can't remember it ever being mentioned.

Of more relevance to JLP, platinum has had a good day up 5%.

Hi WTP

It has been postulated that Immunobody could be used to clear early stage cancer. However, when this statement was made (as part of a peer review as I recall) , the thinking was presumably using the same targets as for late stage cancer i.e. different vaccines for different cancers.

In contrast, this sounds like it is one vaccine to tackle most early stage cancers i.e. the PTM occurs in most cancers.

Thanks Bunsie and, of course, Inan

This is the relevant text

"We have identified a common process that occurs in most cancer that can be recognised by the immune system. This would allow us to design a vaccine to stimulate an immune response which would recognise and kill early cancerous cells. This may have to be boosted yearly as for seasonal flu vaccines. It could be given to people at high risk of cancer or to adults over 60 which are the most common age group for this disease."

This is quite likely to be another post translational modification (PTM) that Lindy has discovered.

This may also be linked to the decision to search for a new lab in Oxford with the aim of furthering PTM research

https://www.lse.co.uk/rns/SCLP/interim-results-for-the-6-months-ended-31-oct-2020-67er6vbha0p3x1z.html

" to support these ongoing activities, and for future programmes, the Company has identified a laboratory facility in Oxford with the aim to expand our translational research, and process development activities to complement the activities of our core research team in Nottingham"

The elephants are also finding it hard to keep feet on the ground :-)
It looks possible that Australia is the next destination but deciding which metal(s) and whose tailings are to be processed is like a game of Cluedo.

It looks like Glencore have a tailings problem (or perhaps 110 of them)

https://www.glencore.com/media-and-insights/news/glencore-enters-partnership-with-tre-altamira-to-expand-satellite-monitoring-across-its-tailings-storage-facilities

"Glencore has entered a global agreement with Tre-Altamira to expand satellite monitoring to over 110 of its dams worldwide making this the largest industry monitoring agreement to date specifically focusing on Tailings Storage Monitoring. "